GCP
PMVP icon

GSA Capital Partners’s PMV Pharmaceuticals PMVP Stock Holding History

GSA Capital Partners’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,441
Closed -$19K – 2081
2026
Q1 		$19K Buy
+15,441
New +$19.6K ﹤0.01% 1642
2024
Q4 		– Sell
-73,352
Closed -$109K – 1932
2024
Q3 		$109K Sell
73,352
-4,391
-6% -$6.78K 0.01% 1479
2024
Q2 		$126K Buy
77,743
+38,106
+96% +$68.7K 0.01% 1510
2024
Q1 		$67K Buy
+39,637
New +$74K 0.01% 1519
2023
Q4 		– Sell
-13,045
Closed -$80K – 1826
2023
Q3 		$80K Sell
13,045
-101,559
-89% -$698K 0.01% 1398
2023
Q2 		$717K Buy
+114,604
New +$601K 0.07% 514

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

GSA Capital Partners's PMVP Position: Q2 2026 in Review

GSA Capital Partners sold out of PMV Pharmaceuticals (PMVP) in Q2 2026, closing a stake of 15,441 shares — an estimated $19K sold.

GSA Capital Partners first reported a position in PMVP in Q2 2023 and held it in 6 quarters. The position peaked at $717K in Q2 2023. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • GSA Capital Partners reported no remaining PMV Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 15,441 PMV Pharmaceuticals shares in Q2 2026, an estimated $19K.
  • GSA Capital Partners first reported a position in PMV Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • GSA Capital Partners's PMV Pharmaceuticals position peaked at $717K in Q2 2023.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.